-
-
-
-
-
-
-
Aura Biosciences adds former Day One CEO to its board
-
-
-
-
-
-
-
Mereo BioPharma Sends Letter to Rubric Capital Management
-
-
-
-
-
-
-
Mission Therapeutics Welcomes Co-founder of Rosetta Capital, Jonathan Hepple, to its Board of Directors
-
-
-
-
-
-
-
Mereo BioPharma (MREO) Reports Positive Feedback from Type B End-of-Ph. 2 Meeting with FDA & Outlines Pivotal Ph. 3 Pediatric Study Design for Setrusumab in Osteogenesis Imperfecta
-
-
-
-
-
-
-
Mereo BioPharma and Oncologie Enter into Global Licensing Agreement for Navicixizumab
-
-
-
-
-
-
-
Mereo BioPharma Announces Setrusumab 6-Month Phase 2b Data in Osteogenesis Imperfecta Selected for Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research (ASBMR) 2019 An
-
-
-
-
-
-
-
Mereo BioPharma Group plc (“Mereo” or the “Company” or the “Group”) Intention to Purchase Shares by Trustee of Employee Benefit Trust
-
1,180,360 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

